CompletedNCT02450890
Evaluate Safety and Efficacy of ORADUR®-Methylphenidate in Children and Adolescents With ADHD
Medication studyAges 6–18Taiwan
Understand this study
Who was this study for?
This study was for people with ADHD. Listed age limits: 6 years to 18 years. Other eligibility criteria applied.
- Listed locations
- Chiayi City, Taiwan · Taipei, Taiwan and 1 more locationSee all locations and recruitment
- Activities
- Placebo comparator · Medication described in the protocol
- Compensation
- Payment and expense reimbursement have not been verified.
Study information
Study start dateJune 2015
- Recruitment status
- Completed
- Enrollment listed in the registry
- 114
- Sponsor
- Orient Pharma Co., Ltd.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Taiwan
- Age range
- From 6 Years to 18 Years
- Official registry ID
- NCT02450890
- Official title
Show the full official title
A Phase III, Multi-Center, Randomized, Double-blind, Placebo Controlled, Two-way Cross-over Clinical Study to Evaluate Safety and Efficacy of ORADUR®-Methylphenidate in Children and Adolescents With ADHD
Recruitment & locations
CompletedChiayi City · Taipei · Taoyuan
Questions about this study
Who is behind this study?
The study sponsor is Orient Pharma Co., Ltd., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including Placebo First, then ORADUR® and ORADUR® First, then Placebo.
Who was this study for?
This study was for people with ADHD. Listed age limits: 6 years to 18 years. Other eligibility criteria applied.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit me